Skip to main content
Clinical Trials/NCT01495442
NCT01495442CompletedNot Applicable

Evaluation of a Dry Powder Aerosol Dispersion Mechanism by Radiolabeling Techniques

University of North Carolina, Chapel Hill1 site in 1 country6 target enrollmentStarted: December 1, 2011Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
6
Locations
1
Primary Endpoint
Fractional delivery of dry powder to the lung

Study Overview

Brief Summary

The primary objective is to admix a radiolabel with albuterol sulphate for incorporation into the Handihaler® device for inhalation studies. This will allow for the investigators to determine the regional lung deposition of drug inhaled from the standard Handihaler® device compared to a novel modification of the device to provide more effective dispersion and aerosolization of the coated albuterol powder. The new mechanism of action for proof-of-concept testing consists of a bead (5.1 mm; expanded polystyrene foam) coated with drug powder, as opposed to the standard lactose formulation-filled capsule.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Basic Science
Masking
Single (Participant)

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •healthy volunteers adults

Exclusion Criteria

  • •chronic illness

Arms & Interventions

modified Handihaler DPI

Active Comparator

Intervention: modified Handihaler DPI (Device)

standard Handihaler DPI

Placebo Comparator

Intervention: standard Handihaler DPI (Device)

Outcomes

Primary Outcomes

Fractional delivery of dry powder to the lung

Time Frame: 1-5 minutes post inhalation

To compare the in vivo performance,i.e. the fraction of drug loaded in device that is delivered to the lung, of the novel system in comparison with a standard marketed dry powder inhaler (DPI) using radio-imaging techniques. The fraction delivered to the lung will be determined by gamma camera imaging of the lungs following inhalation of the radiolabeled powder from the standard vs. new device.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

William Bennett, PhD

Professor of Medicine

University of North Carolina, Chapel Hill

Study Sites (1)

Loading locations...

Similar Trials